Cover Image
市場調查報告書

美國的癲癇市場

Epilepsy Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322803
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
美國的癲癇市場 Epilepsy Market in the US 2015-2019
出版日期: 2015年01月07日 內容資訊: 英文 64 Pages
簡介

美國的癲癇市場預測從2014年到2019年間,將以4.85%年複合成長率擴大。

本報告提供美國的癲癇市場現狀與今後的預測之相關調查,提供您市場成長因素與課題分析,主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 疾病概要

  • 癲癇
    • 病因
    • 徵兆與症狀
    • 診斷
    • 流行病學

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 藥物世代別的市場區隔

第9章 購買標準

第10章 市場成長因素

第11章 成長因素與其影響

第12章 市場課題

第13章 成長因素與課題的影響

第14章 市場趨勢

第15章 趨勢與其影響

第16章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • GlaxoSmithKline
    • UCB
    • Pfizer
  • 其他卓越供應商

第17章 主要供應商分析

  • GlaxoSmithKline
  • Pfizer
  • UCB

第18章 相關報告

目錄
Product Code: IRTNTR5028

About Epilepsy

Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

TechNavio's analysts forecast the Epilepsy market in the US to grow at a CAGR of 4.85 percent over the period 2014-2019.

Covered in this Report

The Epilepsy market in the US can be divided into three segments: First-generation Drugs, Second-generation Drugs, and Third-generation Drugs. This report covers the present scenario and the growth prospects of the Epilepsy market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs approved in the US to treat the symptoms of epilepsy.

TechNavio's report, Epilepsy Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Epilepsy Market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • UCB

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Generic Erosion
  • For a full, detailed list, view our report

Market Trend

  • Reformulation of Marketed Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Epilepsy
    • 05.1.1. Etiology
    • 05.1.2. Signs and Symptoms
    • 05.1.3. Diagnosis
    • 05.1.4. Epidemiology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Generation of Drugs

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Market Share Analysis 2014
    • 16.2.1. GlaxoSmithKline
    • 16.2.2. UCB
    • 16.2.3. Pfizer
  • 16.3. Other Prominent Vendors

17. Key Vendor Analysis

  • 17.1. GlaxoSmithKline
    • 17.1.1. Key Facts
    • 17.1.2. Business Overview
    • 17.1.3. Business Segmentation
    • 17.1.4. Business Segmentation by Revenue 2012 and 2013
    • 17.1.5. Sales by Geography
    • 17.1.6. Pipeline Products
    • 17.1.7. Business Strategy
    • 17.1.8. Key Information
    • 17.1.9. SWOT Analysis
  • 17.2. Pfizer
    • 17.2.1. Key Facts
    • 17.2.2. Business Overview
    • 17.2.3. Business Segmentation by Revenue 2013
    • 17.2.4. Business Segmentation by Revenue 2012 and 2013
    • 17.2.5. Geographical Segmentation by Revenue
    • 17.2.6. Business Strategy
    • 17.2.7. Key Developments
    • 17.2.8. SWOT Analysis
  • 17.3. UCB
    • 17.3.1. Key Facts
    • 17.3.2. Business Overview
    • 17.3.3. Product Segmentation by Revenue 2013
    • 17.3.4. Product Segmentation by Revenue 2012 and 2013
    • 17.3.5. Geographical Segmentation by Revenue 2013
    • 17.3.6. Business Strategy
    • 17.3.7. Recent Developments
    • 17.3.8. SWOT Analysis

18. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Epilepsy Market in the US 2014-2019 (US$ million)
  • Exhibit 3: Epilepsy Market in the US Segmentation by Generation of Drugs
  • Exhibit 4: Prevalence of Active Epilepsy per 1,000 by age in US
  • Exhibit 5: Lamictal Revenue 2011-2013 in the US (US$ million)
  • Exhibit 6: Lamictal Sales Segmentation by Geography 2013
  • Exhibit 7: Vimpat Revenue 2011-2013 in the US (US$ million)
  • Exhibit 8: Vimpat Sales Segmentation by Geography 2013
  • Exhibit 9: Keppra Sales Segmentation by Geography 2013
  • Exhibit 10: Keppra Revenue 2010-2013 in the US (US$ million)
  • Exhibit 11: Lyrica Revenue 2011-2013 in the US (US$ million)
  • Exhibit 12: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 13: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 14: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 15: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 16: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 17: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 18: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 19: UCB: Product Segmentation by Revenue 2013
  • Exhibit 20: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: UCB: Geographical Segmentation by Revenue 2013
Back to Top